Biomarkers for HBV treatment response
AssigneeHoffmann-La Roche Inc.
InventorsLore Gruenbaum, Cynthia Wat, Vedran Pavlovic, Hua He
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods that are useful for predicting the response of hepatitis B virus (HBV) infected patients to pharmacological treatment.
Claims11
A method for treating hepatitis B virus (HBV) infection in a patient, the method comprising:
- (a) detecting the presence of at least one A allele at rs7633796 in gene CADPS on chromosome 3 in a sample obtained from the patient, and
- (b) administering an effective amount of an anti-HBV treatment comprising an interferon to the patient, wherein the patient has at least one A allele at rs7633796 in gene CADPS on chromosome 3, thereby treating HBV infection in the patient.
A method of identifying a patient who may benefit from treatment with an anti-HBV treatment comprising an interferon, the method comprising detecting the presence of a single nucleotide polymorphism in gene CADPS on chromosome 3 in a sample obtained from the patient, wherein the presence of at least one A allele at rs7633796 indicates that the patient may benefit from treatment with the anti-HBV treatment.
A method for predicting hepatitis B ‘e’ antigen (HBeAg) seroconversion and HBV DNA greater than 2000 IU/ml at greater than or equal to 24-week follow-up of treatment (responders vs. non-responders) of an HBe-positive patient infected with HBV to interferon treatment comprising:
- (a) providing a sample from the patient,
- (b) detecting the presence of a single nucleotide polymorphism in gene CADPS on chromosome 3, and
- (c) determining that the patient has a high response rate to interferon treatment measured as HBeAg seroconversion and HBV DNA greater than 2000 IU/ml at greater than or equal to 24-week follow-up of treatment (responders vs. non-responders) if at least one A allele at rs7633796 is present in the patient.
Dependencies are inferred from the claim text.